← FDA DRUG APPROVALS

FDA ANDA · ANDA075690

FLUOXETINE HYDROCHLORIDE

Sponsor: ACTAVIS MID ATLANTIC

APPLICATION
ANDA075690
TYPE
ANDA
ORIGINAL APPROVAL
2002-01-31
LATEST ACTION
2023-08-18
ROUTE
ORAL
DOSAGE FORM
SOLUTION
MARKETING STATUS
Discontinued

Products

FLUOXETINE HYDROCHLORIDEDiscontinued
FLUOXETINE HYDROCHLORIDE EQ 20MG BASE/5ML · SOLUTION · ORAL

Approval history

2023-08-18Labeling · Supplement 9 · standardAP
2021-09-20Labeling · Supplement 8 · standardAP
2002-12-17Manufacturing (CMC) · Supplement 1AP
2002-01-31OriginalLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →